Medherant - Revision history

Waza: Remove deletion discussion templates and unavailable templates

2026-10-05T03:15:34Z

Remove deletion discussion templates and unavailable templates

@@ Line 1: / Line 1: @@
 '''Medherant Ltd''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].
@@ Line 30: / Line 8: @@
 Using its research in [[bioadhesive|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal |last=Efstathiou |first=Spyridon |last2=Nurumbetov |first2=Gabit |last3=Ross |first3=Andrew |last4=Li |first4=Yongguang |last5=Haddleton |first5=David M. |date=2024-04-22 |title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) |url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f |journal=Materials Advances |language=en |volume=5 |issue=8 |pages=3396–3410 |doi=10.1039/D3MA01104F |issn=2633-5409|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches  via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=http://www.medherant.co.uk/about-us |title=Medherant - About Us |publisher=Medherant Ltd |accessdate=16 October 2016}}</ref>
-Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news |date=2023-04-03 |title=Menopause testosterone patch to begin trials |url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 |access-date=2025-10-24 |work=BBC News |language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite press release |title=Medherant announces positive Phase 1 clinical trial results |url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results |access-date=2025-10-24 |website=warwick.ac.uk | publisher = University of Warwick  }}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact|date=October 2026}}
+Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news |date=2023-04-03 |title=Menopause testosterone patch to begin trials |url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 |access-date=2025-10-24 |work=BBC News |language=en-GB}}</ref> which has shown excellent results to date.<ref>[https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results "Medherant announces positive Phase 1 clinical trial results"] ''warwick.ac.uk''. University of Warwick. Retrieved 2025-10-24.</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact|date=October 2026}}
 ==References==

Waza: 26 revisions imported: Import with full history

2026-10-05T02:58:28Z

26 revisions imported: Import with full history

← Older revision	Revision as of 02:58, 5 October 2026
(No difference)

wikipedia>AnomieBOT: Dating maintenance tags: {{Fact}}

2026-10-05T02:33:41Z

Dating maintenance tags: {{Fact}}

← Older revision		Revision as of 02:33, 5 October 2026
Line 25:		Line 25:
	==History==		==History==
	Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton\|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.		Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton\|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
	Started as a research project in Haddleton Group at the University of Warwick in 2013, the company has operated at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and had received over £15M investment by the end of 2025.{{fact}}		Started as a research project in Haddleton Group at the University of Warwick in 2013, the company has operated at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and had received over £15M investment by the end of 2025.{{fact\|date=October 2026}}

	==Research==		==Research==
	Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409\|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant - About Us \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>		Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409\|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant - About Us \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>

	Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite press release \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk \| publisher = University of Warwick }}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact}}		Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite press release \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk \| publisher = University of Warwick }}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact\|date=October 2026}}

	==References==		==References==

wikipedia>Guliolopez: Refs and ref syntax. Copyedits

2026-10-05T02:13:18Z

Refs and ref syntax. Copyedits

← Older revision		Revision as of 02:13, 5 October 2026
Line 25:		Line 25:
	==History==		==History==
	Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton\|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.		Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton\|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
	Started as a research project in Haddleton Group at the University of Warwick in 2013, the company ~~operates~~ at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and ~~has~~ received over £15M investment by the end of 2025.		Started as a research project in Haddleton Group at the University of Warwick in 2013, the company has operated at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and had received over £15M investment by the end of 2025.{{fact}}

	==Research==		==Research==
	Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409\|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant ~~is developing a first~~-~~in-class transdermal drug delivery patch for prescription and OTC medicines~~ \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>		Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409\|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant - About Us \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>

	Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite ~~web~~ \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].		Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite press release \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk \| publisher = University of Warwick }}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].{{fact}}

	==References==		==References==
Line 36:		Line 36:

	==External links==		==External links==
	* [~~http~~://www.~~haddleton~~.~~org Haddleton Group~~]		* [https://www.medherant.co.uk/ Medherant.co.uk]

	[[Category:University of Warwick]]		[[Category:University of Warwick]]

wikipedia>Hitaki-oro: Nominated for deletion; see :Wikipedia:Articles for deletion/Medherant.

2026-10-04T18:13:08Z

Nominated for deletion; see Wikipedia:Articles for deletion/Medherant.

← Older revision		Revision as of 18:13, 4 October 2026
Line 1:		Line 1:
			<!-- Please do not remove or change this AfD message until the discussion has been closed. -->
			{{Article for deletion/dated\|page=Medherant\|timestamp=20261004181308\|year=2026\|month=October\|day=4\|substed=yes\|help=off}}
			<!-- Once discussion is closed, please place on talk page: {{Old AfD multi\|page=Medherant\|date=4 October 2026\|result='''keep'''}} -->
			<!-- End of AfD message, feel free to edit beyond this point -->
	{{POV\|date=August 2023}}		{{POV\|date=August 2023}}
	{{Short description\|British pharmaceutical company}}		{{Short description\|British pharmaceutical company}}

~2026-35820-09: fix lead, add cats

2026-06-19T13:24:29Z

fix lead, add cats

← Older revision		Revision as of 13:24, 19 June 2026
Line 14:		Line 14:
	\| hq_location_city = Coventry		\| hq_location_city = Coventry
	\| hq_location_country = United Kingdom		\| hq_location_country = United Kingdom
	\| website = {{~~Official website~~ \|~~www.~~medherant.co.uk}}		\| website = {{URL\|medherant.co.uk}}
	}}		}}

	'''~~[https://www.medherant.co.uk/~~ Medherant Ltd]''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].		'''Medherant Ltd''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].

	==History==		==History==
Line 34:		Line 34:
	* [http://www.haddleton.org Haddleton Group]		* [http://www.haddleton.org Haddleton Group]

			[[Category:University of Warwick]]
	[[Category:Companies based in Coventry]]		[[Category:Companies based in Coventry]]
	[[Category:Pharmaceutical companies of the United Kingdom]]		[[Category:Pharmaceutical companies of the United Kingdom]]
			[[Category:University spin-offs]]

wikipedia>OAbot: Open access bot: doi updated in citation with #oabot.

2025-11-24T05:11:12Z

Open access bot: doi updated in citation with #oabot.

← Older revision		Revision as of 05:11, 24 November 2025
Line 24:		Line 24:

	==Research==		==Research==
	Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>		Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409\|doi-access=free }}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>

	Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite web \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].		Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite web \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

137.205.213.65: added wiki link to david haddleton

2025-10-24T11:58:49Z

added wiki link to david haddleton

← Older revision		Revision as of 11:58, 24 October 2025
Line 20:		Line 20:

	==History==		==History==
	Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.		Medherant Ltd was founded as a [[university spin-off]] by [[David Haddleton\|Professor David Haddleton]] and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
	Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.		Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.

137.205.213.65: added bbc reference

2025-10-24T11:56:55Z

added bbc reference

← Older revision		Revision as of 11:56, 24 October 2025
Line 26:		Line 26:
	Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>		Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>

	Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women which has shown excellent results to date.<ref>{{Cite web \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].		Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women<ref>{{Cite news \|date=2023-04-03 \|title=Menopause testosterone patch to begin trials \|url=https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981 \|access-date=2025-10-24 \|work=BBC News \|language=en-GB}}</ref> which has shown excellent results to date.<ref>{{Cite web \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

	==References==		==References==

137.205.213.65: updated material and added recent citations

2025-10-24T11:55:37Z

updated material and added recent citations

← Older revision		Revision as of 11:55, 24 October 2025
Line 17:		Line 17:
	}}		}}

	'''Medherant Ltd''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company ~~develops~~ [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].		'''[https://www.medherant.co.uk/ Medherant Ltd]''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]].

	==History==		==History==
	Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.		Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system.
	Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014.		Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014 and has received over £15M investment by the end of 2025.

	==Research==		==Research==
	Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company ~~intends~~ to introduce patches ~~in 2019 which are able to deliver drugs~~ via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>		Using its research in [[bioadhesive\|polyurea based pressure sensitive adhesive]]s<ref>{{Cite journal \|last=Efstathiou \|first=Spyridon \|last2=Nurumbetov \|first2=Gabit \|last3=Ross \|first3=Andrew \|last4=Li \|first4=Yongguang \|last5=Haddleton \|first5=David M. \|date=2024-04-22 \|title=Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD) \|url=https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f \|journal=Materials Advances \|language=en \|volume=5 \|issue=8 \|pages=3396–3410 \|doi=10.1039/D3MA01104F \|issn=2633-5409}}</ref> and [[polymer chemistry]], the company is working to introduce transdermal drug delivery patches via the trans[[epidermal]] route.<ref>{{cite web \|url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ \|title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin \|publisher=University of Warwick \|accessdate=16 October 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web \|url=http://www.medherant.co.uk/about-us \|title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines \|publisher=Medherant Ltd \|accessdate=16 October 2016}}</ref>

	Medherant is also developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]]~~, with plans to release its first product on the market by 2019~~.		Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women which has shown excellent results to date.<ref>{{Cite web \|title=Medherant announces positive Phase 1 clinical trial results \|url=https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results \|access-date=2025-10-24 \|website=warwick.ac.uk}}</ref> Medherant has also been developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]].

	==References==		==References==